SCHEMBL829233

SCHEMBL829233

CCN1C(=O)NC(=O)C(C)(N)C1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.37
ELANE P08246 1/20 0.37
CTSG P08311 1/20 0.37
CTRC Q99895 1/20 0.37
LMNA P02545 2/20 0.33
POLB P06746 1/20 0.33
GMNN O75496 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
THPO P40225 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MGLL Q99685 1/20 0.33
CYP2C19 P33261 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
BACE1 P56817 1/20 0.31
BACE2 Q9Y5Z0 1/20 0.31
KDM4E B2RXH2 1/20 0.30
CHRM2 P08172 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL828019 0.82 SMN1; SMN2 (0.39) POLBALDH1A1MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL829408 0.76 SMN1; SMN2 (0.37) F2ELANECTSGCTRCLMNA
SCHEMBL31213553 0.72 LMNA (0.48) F2ELANECTSGCTRCLMNA
Hydrochloric Acid SCHEMBL829197 0.70 MEN1 (0.39) LMNA
SCHEMBL5584023 0.67 POLB (0.71) F2ELANECTSGCTRCLMNA
SCHEMBL2046819 0.66 LMNA (0.41) F2ELANECTSGCTRCLMNA
Hydrochloric Acid SCHEMBL829889 0.65 MAPT (0.34) ALDH1A1MAPT
SCHEMBL825911 0.65
SCHEMBL16922376 0.64 ELANE (0.50) F2ELANECTSGCTRCLMNA
SCHEMBL10953690 0.64 ELANE (0.50) F2ELANECTSGCTRCLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004614-B1 TETRAHALOGENATED COMPOUNDS USEFUL AS INHIBITORS OF ANGIOGENESIS US GOV HEALTH & HUMAN SERV (US) 2016-10-19 EP disclosed
US-8143252-B2 Tetrahalogenated compounds useful as inhibitors of angiogenesis THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-03-27 US disclosed
US-20090186913-A1 Tetrahalogenated compounds useful as inhibitors of angiogenesis THE GOVERNMENT OF THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186913-A1 Tetrahalogenated compounds useful as inhibitors of angiogenesis VHL, TEK, FLT4 F2 4319/4885ELANE 438/4885CTSG 1121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.